Cargando…
Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis
SIMPLE SUMMARY: Immunotherapy is an emerging treatment in hepatocellular carcinoma, both alone and in combination. The advent of this new approach raises challenges for the interpretation of response assessment due to the peculiar patterns of mixed responses, pseudoprogression and hyperprogression....
Autores principales: | Rapposelli, Ilario Giovanni, De Matteis, Serena, Lanuti, Paola, Valgiusti, Martina, Bartolini, Giulia, Ulivi, Paola, Marisi, Giorgia, Pedica, Federica, Burgio, Valentina, Frassineti, Giovanni Luca, Cascinu, Stefano, Casadei-Gardini, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827490/ https://www.ncbi.nlm.nih.gov/pubmed/33430142 http://dx.doi.org/10.3390/cancers13020213 |
Ejemplares similares
-
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
por: Marisi, Giorgia, et al.
Publicado: (2018) -
IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2018) -
Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2017) -
Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
por: Ulivi, Paola, et al.
Publicado: (2017) -
Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer
por: Canale, Matteo, et al.
Publicado: (2021)